©2021-2032  All Rights Reserved. Online Journal of Bioinformatics.  You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides  the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to onlinejournals@gmail.com publications. This article may be copied once but may not be, reproduced or  re-transmitted without the express permission of the editors. Linking: To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.

OJBTM

Online Journal of Bioinformatics©

Established 1995

ISSN  1443-2250

 

Volume 24 (1):13-25, 2023.

In silico isoform inhibitors for class I pan P13K therapeutics toxicity.

  

Awantika Shrivastava1, K Durga Prasad 1, Archana Giri 2

 

1Natco Research Centre, B-13, Industrial estate, Sanath Nagar, Hyderabad, 2Department of Biotechnology, JNTU, Kukatpally, Hyderabad, India

 

Shrivastava A, Prasad KD, Giri A., In silico isoform inhibition for class I pan P13K therapeutics toxicity, Onl J Bioinform., 24 (1): 13-23, 2023. Class I Pan PI3K therapeutic inhibitors were found to induce toxicity in clinical trials. However, isoform inhibitors may reduce or prevent toxicity. We report In silico docking and binding isoform inhibitors GS-1101 over Class I PI3K GDC-0941, WORTMANNIN & LY294002. GS-1101 were docked to binding site of isoforms 3DBS (p110 Gamma), 2Y3A (pI3k BETA), 2WXP (PI3K DELTA) & 4A55 (P110 Anthocyanin ALPHA) and then compared docking with Class I Pan PI3K GDC-0941 inhibitor. Docking of GS-1101 bound to all PI3K isoforms was subjected to molecular dynamics studies.

Keywords- Molecular docking studies, sequence Analysis, PI3K, ligandfit.

MAIN

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)